Clinical Trials
33 trialsTesting the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
STARTRK-2
Hoffmann-La Roche
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Northwestern University
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
PTC-RFA
University Health Network, Toronto
IoN
University College, London
PRO-COMAND
University of Pisa
Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors
Mayo Clinic
Decision Aid Efficacy in Low Risk Thyroid Cancer
University of Maryland, Baltimore
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
LIBRETTO-001
Eli Lilly and Company
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
University of Michigan Rogel Cancer Center
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
STRAP
National Cancer Centre, Singapore
STARTRK-NG
Hoffmann-La Roche
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
DETERMINE
Cancer Research UK
MAPS
University of California, Los Angeles
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
IDENTHY-K
Nantes University Hospital
MHI
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
LIBRETTO-121
Eli Lilly and Company
Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma
China-Japan Friendship Hospital
Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
DETERMINE
Cancer Research UK
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma
Chinese PLA General Hospital
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
AHS Cancer Control Alberta